Table 1 Primary endpoint of spleen volume response rate >35% (SVR35) at week 24 in a subgroup analysis of the JAKARTA trial, by reason for ruxolitinib discontinuation.

From: Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data

 

SVR35 at week 24

Original analysis (Per protocol, n = 83)

Resistant (n = 55)

53%

Resistant - insufficient response (n = 19)

53%

Resistant – disease progression (n = 13)

38%

Resistant – loss of response (n = 23)

61%

Intolerant (n = 27)

63%

Updated analysis (Intention to treat, n = 97)

Resistant (n = 64)

33%

Intolerant (n = 32)

28%

Stringent Criteria Cohort - Relapsed/refractory (n = 65)

31%

Stringent Criteria Cohort - Intolerant (n = 14)

29%

  1. Results from the original per protocol analysis vs the intention to treat analysis and the investigator assessment method vs stringent criteria of the updated analysis are shown.
Back to article page